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InﬂammationPulmonary surfactant protein-D (SP-D) is a soluble collagenous C-type lectin with important anti-microbial and
anti-inﬂammatory properties. Although it is subject to functionally relevant modiﬁcation by common polymor-
phisms and unregulated inﬂammation, the functional status of SP-D in cystic ﬁbrosis (CF) remains unclear. Given
the importance of infection and inﬂammation in CF lung pathology we have undertaken the ﬁrst systematic
analysis of SP-D lectin activity in this population. By ELISA, we found that airway lavage ﬂuid SP-D expression
was greater in CF compared to control patients but was reduced in CF patients with infection and correlated
negatively with markers of neutrophilic inﬂammation. In a functional assay, the percentage of SP-D capable of
binding zymosan rarely exceeded 60% in CF or control patients and similarly restricted binding activity was ob-
served towards maltose–agarose. SP-D lectin activity also correlated negatively with infection and neutrophilic
inﬂammation but there was little evidence of major proteolytic degradation amongst the non-bound material.
SP-D which failed to bind zymosan exhibited features of lower oligomeric form compared to bound material
when tested by native gel electrophoresis. Furthermore, when separated by gel chromatography, high and
low oligomeric populations of SP-D were observed in CF lavage ﬂuid but only high oligomeric forms exhibited
substantial lectin activity towards yeast derived mannan. Our data demonstrate that oligomeric heterogeneity
underlies functional diversity amongst SP-D in health and disease and that dynamic regulation of oligomerisation
is an important feature of SP-D biology.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Surfactant protein-D (SP-D) is a soluble multimeric collagenous C-
type lectin. Although initially and most widely described as a lung spe-
ciﬁc protein, SP-D is also expressed at a number of other mucosal siteshe design and execution of clin-
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ights reserved.[1]. In common with other collectins including mannose binding lectin
(MBL) and surfactant protein-A (SP-A), SP-D recognises carbohydrate
structures on a wide range of pathogens – including viruses, bacteria
and fungal species – in a calcium dependent fashion [2]. The conse-
quences of such recognition vary amongst the collectins and in the
case of SP-D, pathogen agglutination, inhibition of replication and en-
hanced phagocytosis are the primary outcomes. Clearly important, but
less well understood, is the ability of SP-D to regulate inﬂammatory
activity. This aspect of SP-D biology is most apparent in the knockout
mousewhich develops a spontaneous and progressive emphysematous
inﬂammatory lung disease [3].
SP-D expression has been examined in a number of lung diseases,
including cystic ﬁbrosis (CF). Exacerbations characterised by protracted
and ineffective neutrophil dominated inﬂammatory responses to pul-
monary infection are a primary cause of progressive lung damage in
CF and for this reason there has been much interest in the pulmonary
innate immune system in this population. Although a number of studies
have been undertaken, a clear consensus on the status of SP-D in CF has
not emerged. Earlier studies demonstrated a near absence of SP-D in CF
lung secretions [4], but more recently μg/ml quantities have been
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reports of a complete absence [5], or signiﬁcant reduction [4,6] of SP-D
expression in CF patients with infection contrast with others demon-
strating relatively abundant immunoreactive SP-D in patients infected
with Pseudomonas aeruginosa [7]. Whilst the amount of detectable SP-
D in CF BALF correlates negatively with markers of neutrophil activity
and SP-D is susceptible to neutrophil mediated inactivation in vitro
[5–10], the functional status of endogenous SP-D in CF lung secretions
has not been systematically addressed. This is important as physiologi-
cal concentrations of calcium are known to protect SP-D from neutro-
phil mediated protease inactivation [6,9–11] and in some studies
little or none of the SP-D found in CF exhibits features of proteolytic
degradation [7,12].
For this reason we wished to examine whether the widely reported
inactivation of SP-D by neutrophils in vitro is reﬂected in the functional
status of this molecule in CF lung secretions. Here we examine the ex-
pression of SP-D in airway secretions from two independent CF cohorts
and control patients. We also report the ﬁrst systematic assessment of
the SP-D lectin activity in CF using a novel zymosan binding assay.2. Materials and methods
2.1. Patient recruitment and sample processing
Sampleswere included from two independently collected cohorts of
CF patients and a cohort of control patients (see Table 1) as follows:
Cohort A (25 samples) was recruited from the Children's CF unit at
the University Hospital of Wales as previously described [13]. Lavage
was collected by ﬂexible bronchoscopy in 10/25 cases with the remain-
der collected by non-bronchoscopic lavage. In all cases lavage was
conducted for diagnostic reasons by instillation of 1ml/kg normal saline
(up to a maximum of 20ml) which was immediately suctioned back. A
portion of this lavage, representing the bronchial airway, was available
for this study. Processing and storage of lavage ﬂuid at−80°C occurred
within 45min of collection as previously described [13]. Brieﬂy, lavage
ﬂuid was centrifuged at 500 g/5 min at 4 °C, cell free lavage was
aliquoted at 25 μl and stored at −80 °C for later analysis. Amongst CF
cohort A, clinically signiﬁcant microbes were cultured from 10 samples
(P. aeruginosa (n=5), Burkholderia cepacia (n=1), Stenotrophomonas
maltophilia (n = 2; of which n = 1 coincident with P. aeruginosa),
Aspergillus fumigatus (n=1),Moraxella catarrhalis (n=1),Haemophilus
inﬂuenzae (n= 2; of which n= 1 coincident with M. catarrhalis)). 15
samples either yielded no culturable microbes or yielded microbes sug-
gestive of normal microﬂora (Klebsiella pneumoniae, alpha haemolyticTable 1
Description of cohorts under study.
Control
N 9
Age (decimal years) 8.28 (6.53–10.93)
Sex (M:F) 5:4
Weight (kg) NK
BMISDS NK
FEV1 (% predicted) NK
FVC (% predicted) NK
Lavage culture veriﬁed infection (N) 0
Lavage neutrophils (106/ml) 0.007 (0–0.0157)
Lavage mononuclear cells (106/ml) 0.096 (0.0047–0.38)
Lavage elastase positive:negative (N) 0:9
Lavage free elastase activity (nM)e 0
Data are expressed as median (range) or as number of samples (N).
a NK=not known.
b Lung function data were available for a proportion of cohort A and B and were not availab
c Please see materials and methods for additional information.
d Differential cell counts were available for a proportion of the cohort as previously describe
e Elastase activity values refer to elastase positive samples only.streptococci) or microbes not considered to be of clinical signiﬁcance in
the absence of other symptoms (Candida, coliforms).
Control lavagewas collected by non-bronchoscopic lavage fromnine
non-CF subjects who were undergoing tonsillectomy and/or adenoid-
ectomy at the University Hospital of Wales. These patients were well
at the time of surgery andwere not in receipt of medication for respira-
tory symptoms as previously reported [13]. Samples were processed
and stored as described for CF cohort A. For this cohort and CF cohort
A, ethical approval was obtained from the South East Wales Local Re-
search Ethics Committee and written informed consent was obtained.
Cohort B (19 samples)was recruited as previously described [11] from
SouthamptonGeneral Hospital fromchildren undergoingﬁberoptic bron-
choscopy for diagnostic reasons. For cohort B, 3×10ml portions of normal
salinewere instilled and aspirated in children younger than 3years of age.
This was increased to 3×20ml portions in children N3years of age. This
sampling represents bronchoalveolar lavage (BAL). The study was ap-
proved by the Southampton and Wessex Local Research Ethics Commit-
tees and written informed consent was obtained from the parents. BAL
from cohort B was initially ﬁltered through a 100 μm nylon cell strainer
(BD Biosciences) prior to centrifugation at 500g/10min at 4°C. Aspirated
cell free BALF was immediately stored at−80°C. For this study, 1ml ali-
quots from cohort B were available. Consequently, one freeze/thaw cycle
was undertaken on these samples to prepare 25μl aliquots subsequently
used throughout the study. A single freeze thaw step was found to have
no discernible impact on SP-D binding activity and recovery when deter-
mined for three lavage ﬂuid samples (data not shown). Limited clinical
data and nomicrobiology data were available for cohort B and this cohort
was primarily used to independently replicate observations made with
themain cohort A. Owing to somedifferences in collection andprocessing
methodologies, no direct comparison was made between cohort B and
either cohort A or the control cohort.
Immediately prior to analysis, samples from both cohorts were
thawed on ice and subjected to micro-centrifugation at 10,000 g
for 1 min. Not all samples from the original studies were available for
analysis here.
2.2. Reagents
Unless otherwise stated, all reagents were from Fisher Scientiﬁc
(Loughborough, UK). Afﬁnity puriﬁed goat anti-human SP-D raised
against recombinant human SP-D was from R&D systems (Abingdon,
UK). Minimally cross reactive HRPO-conjugated donkey anti-goat IgG
was from Jackson ImmunoResearch (Suffolk, UK). Native SP-D was
puriﬁed from pulmonary alveolar proteinosis bulk lavage as previously
described [14], and stored at−80°C in the presence of 1mM EDTA.CF cohort A CF cohort B
25 19
6.41 (0.07–15.74) 9.67 (0.39–17.92)
15:10 NKa
22 (4.8–81.2) NK
0.09 (−7.7–3) NK
80 (37–110); (N=12)b 82.2 (68–145); (N=12)b
88.5 (51–106); (N=12)b 88.45 (73–161); (N=12)b
10c NK
0.54 (0.03–4); (N=18)d NK
0.4 (0.04–2.5); (N=18)d NK
14:11 11:8
74 (8–1250) 40 (2–1657)
le for children b4 years of age.
d [13].
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SP-Dwas quantiﬁed in lavage ﬂuid using a twomonoclonal antibody
sandwich ELISA from Hycult Biotech (Uden, Netherlands) according to
the manufacturer's instructions (measurable range: 6.3–400 ng/ml).
Lavage samples were diluted between 1:2 and 1:100 and measured in
duplicate. Values for IL-8 have previously been reported in cohort A
[13] but not in the context of SP-D expression; this novel analysis is
reported here.
2.4. Activity assays
Values for elastase activity in cohorts A and B have been previously
reported [11,13] but not in the context of SP-D expression; this novel
analysis is reported here.
2.5. Zymosan and maltose–agarose binding assays
10 μl of a Zymosan-A suspension (1% w/v in 154 mM NaCl) was
added to a 0.5 ml microcentrifuge tube and washed twice with 10
volumes of TBS-Ca (20 mM Tris-HCl, 154 mM NaCl, 20 mM CaCl2;
pH 7.6) with microcentrifugation at 10,000 g (13,000 rpm at r =
5.3 cm) for 1 min between washes. The pellet was resuspended
with 10 μl of TBS-Ca and 10 μl of either freshly thawed BALF or, as a
positive control, 10 μl of native SP-D diluted to 2 or 20 μg/ml in
154 mM NaCl with 1.5 mg/ml protease free BSA (Sigma, Dorset,
UK) to give a ﬁnal concentration of 10mM CaCl2 in all binding assays.
Where Ca2+ or carbohydrate dependence of the binding assay was
tested, native SP-D or lavage was diluted to give a ﬁnal concentration
of 10mM EDTA in TBS or 100mM D-Maltose plus 10mM CaCl2 in TBS
in the binding assay. In some cases, 1mM PMSF was included to in-
hibit serine protease activity in assays where EDTA was used.
Where the capacity of lavage to inﬂuence native SP-D binding to
zymosan was tested, 10 μl of native SP-D (2 μg/ml) in TBS-Ca was
pre-incubated with 10μl of lavage prior to incubation with zymosan.
For all assay formats, samples were incubated for 30 min at 37 °C
with occasional gentle mixing to maintain zymosan in suspension
over the course of the assay. Post assay, samples were micro-
centrifuged at 10,000 g for 1min and the supernatant was carefully
aspirated to a fresh tube, avoiding disturbance of the zymosan pellet.
Following aspiration of the supernatant, the zymosan pellet was
washed once with 100 μl TBS-Ca as described above and the washed
pellet was resuspended in 20 μl TBS with 20mM EDTA. Where sam-
ples were subsequently subjected to SDS-PAGE both pellet and su-
pernatant fractions were immediately treated with SDS sample
buffer with β-mercaptoethanol as a reducing agent and boiled at
100 °C for 2 min prior to electrophoretic separation. For native-
PAGE, samples were treated with cold sample buffer without SDS
but supplemented with 0.002% Coomassie Blue G250 (Sigma, UK).
Samples were not boiled but immediately separated as described
below. The reproducibility of the zymosan binding assay was con-
ﬁrmed by assaying at least seven lavage samples from this and a pre-
vious study [15] at different time points up to 10 months apart
(data not shown).
Maltose–agarose pull down assays were similar to the zymosan
binding assays with the following differences. 10 μl of maltose aga-
rose (Sigma, Dorset, UK) was washed three times in 1 ml TBS-Ca
prior to commencement of the binding assay. Binding steps for
both parallel zymosan and maltose–agarose assays were carried
out on a ﬂat bed roller to avoid settling of the maltose–agarose dur-
ing the assay. Assays were carried out in a ﬁnal volume of 30μl, with
only 20 μl of the supernatant fraction aspirated for SDS-PAGE to
avoid disturbing the agarose pellet; once washed, the pellet was
resuspended in 30 μl of TBS-EDTA, 20 μl of which was prepared for
SDS-PAGE as described above.2.6. Native- and SDS-PAGE, western blot and densitometry
Native PAGE was performed using NuPage 3–8% Tris-Acetate gels
(Life Technologies, UK) and a tris-glycine buffer system where the
cathode buffer was supplemented with 0.002% Coomassie Blue G250.
Electrophoresis proceeded for 90–120 min at a constant voltage of
150V. Proteinswere transferred to nitrocellulose usingNuPage Transfer
buffer (Life Technologies, UK) supplemented with 10% methanol at a
constant voltage of 100 V for 1 h. For proteins separated under dena-
tured and reduced conditions SDS-PAGE was performed using 10%
gels with a 4% stacking gel. Gels were separated at a constant current
of 45mA per gel for 45–60min. Proteins were transferred to nitrocellu-
lose in a tris-glycine buffer supplemented with 20% methanol at a con-
stant voltage of 100 V for 1 h. In all cases, following transfer to
nitrocellulose, blots were blocked for 30 min at room temperature
with PBS 5%w/v skimmedmilk powder (PBS-milk). Blots were incubat-
ed overnight at 4 °C with 0.1 μg/ml goat anti-human SP-D in PBS-milk.
Blots were washed three times with PBS-0.05% v/v Tween and once
with PBS. Blots were incubated with minimally cross-reactive HRPO-
conjugated donkey anti-goat IgG for 45 min at room temperature,
washed three times with PBS-Tween, three times with PBS and devel-
oped using ECL prime substrate (GE Lifesciences, UK) prior to exposure
to X-Ray ﬁlm (Fuji, UK). The limit of sensitivity of SP-D detection by
western blot was approximately 5 ng/lane (equivalent to 500 ng/ml
under the conditions used here) and lavage samples with ELISA deter-
mined SP-D below this level were not detectable by western blot in
this study.
Developed blots were scanned and the entire blot areawas uniform-
ly adjusted for brightness and contrast. Presented images represent all
bands visible in lanes from the original blot. Densitometry was per-
formed on the blots using ImageJ v1.42 as previously described [13]
and percentage zymosan bound SP-D for any given data point refers
to the percentage of the total band area present in the pellet fraction.
As SP-D exists in a number of oligomeric forms of differing molecular
weights, densitometry was only undertaken on samples reduced with
β-mercaptoethanol immediately prior to SDS-PAGE. Reducing all SP-D
oligomeric forms to single subunits ensured equivalent transfer efﬁcien-
cy and antibody reactivity of bands in pellet and supernatant fractions
during western blot which is essential for accurate comparison of SP-
D content in each fraction.
2.7. Analytical gel ﬁltration and mannan binding assays
Lavageﬂuid (200μl) from six CF patientswas applied to a Superose 6
10/300GL (GE Lifesciences, UK) column and was eluted in TBS-1 mM
EDTA at a ﬂow rate of 24ml/h on an AKTAprime (GE Lifesciences, UK),
collecting 0.8 ml fractions which were immediately transferred to ice.
Fractions were assayed for SP-D by a sandwich ELISA as described
[41], except the capture antibody was replaced with a polyclonal
rabbit antibody raised against a recombinant fragment of human SP-D,
as previously reported [16]. Plates were developed with 3,3′,5,5′-
Tetramethylbenzidine (TMB) (Sigma, UK) and arrested with H2SO4 be-
fore absorbance wasmeasured at 450nm on a SpectraMax 340PC spec-
trophotometer (Molecular Devices, UK).
Fractions were also assayed for speciﬁc SP-D lectin activity in a solid
phase mannan binding assay as follows: Maxisorp 96-well plates
(Nunc, Denmark) were coated overnight at 37°Cwith 50μg/mlmannan
from Saccharomyces cerevisiae (Sigma, UK) and blocked with TBS 0.05%
Tween 20 (TBST). Gel chromatography fractionsweremade 0.05% (v/v)
with respect to Tween 20 and 10 mM with respect to either CaCl2 or
EDTA. Fractions were applied to mannan coated plates for 90 min at
room temperature. Plates were washed three times with TBST-10mM
calcium (TBST-C) or TBST-10 mM EDTA (TBST-E) and goat anti-SP-D
(1μg/ml) was applied in TBST-C for 60min at room temperature. Plates
were washed and HRPO-conjugated minimally cross reactive donkey
anti-goat IgG was applied for 30min at room temperature. Plates were
Fig. 2. SP-D expression negatively correlates with age in CF: Lavage SP-D concentration
was plotted against patient age in CF cohort A (n = 25). The r- and p-values refer to
Spearman's rank correlation. As stated in the text, a similarly signiﬁcant correlation
between age and SP-D concentration was also observed in CF cohort B (data not shown;
Spearman r=−0.47; p= 0.04).
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bancewasmeasured at 450nmon a SpectraMax 340PC spectrophotom-
eter (Molecular Devices, UK).
2.8. Statistics
Unless otherwise indicated, all data presented in the text refer to
(median; interquartile range). Two group comparisons of non-
parametric data were undertaken using the Mann–Whitney test.
Spearman's r-values are used to describe correlations. In all cases statis-
tical signiﬁcance was achieved at p b 0.05. Data remained statistically
signiﬁcant after the application of Holm's sequential Bonferroni correc-
tion where appropriate [17]. All data were analysed using GraphPad
Prism v5.01 (GraphPad Software Inc.).
3. Results
3.1. SP-D expression in CF airway lavage ﬂuid is inversely related to
infection, markers of neutrophilic inﬂammation and age
SP-D was detected by ELISA in CF lavage ﬂuid from cohort A
(5332 ng/ml; 1957–9595) at levels 2.4 fold higher than control BALF
(2214ng/ml; 1545–2902) (Fig. 1A).Within CF cohort A SP-D expression
was 3.6 fold lower in those with clinically important infections
(1892 ng/ml; 359–6376) compared to those without (6879 ng/ml;
4683–12200) (Fig. 1B). SP-D expression negatively correlatedwith elas-
tase activity (data not shown: Spearman r=−0.71; p=0.004) and IL-8
expression (data not shown: Spearman r=−0.45; p=0.02) in CF co-
hort A. SP-D expression also negatively correlated with age in CF cohort
A (Fig. 2: Spearman r=−0.4; p=0.04). Patients in whom elastase ac-
tivitywas detectedwere signiﬁcantly older than elastase negative coun-
terparts (9.2years; 3.6–13.2 vs. 2years; 0.7–6.4: p=0.02) and infected
patients were also substantially older than their non-infected counter-
parts (8.7 years; 3.6–13.5 vs. 2.8 years; 0.4–8.8) although this did not
reach statistical signiﬁcance (p=0.08). Data formicrobiology or IL-8 ex-
pression were not available for cohort B (median BALF SP-D:
1073 ng/ml; 239–2414), however we conﬁrmed that SP-D expression
correlated negatively both with elastase activity (data not shown:
Spearman r=−0.8; p= 0.002) and age (data not shown: Spearman
r=−0.47; p=0.04).
3.2. Measuring SP-D lectin activity with a functional assay
SP-D lectin activity was measured in a zymosan binding assay.
Native SP-D interactions with zymosan were maltose and EDTAFig. 1. SP-D expression in CF and control lavage ﬂuid: A) SP-D was measured in CF cohort A (n
samples inwhich clinically relevantmicroorganisms were recovered (infection status positive;
isms regarded either as part of the normal microﬂora or not clinically signiﬁcant (infection statu
are as follows: P. aer.=Pseudomonas aeruginosa, H. Inﬂ.=Haemophilus inﬂuenzae, B. cep.=Bur
M. cat. =Moraxella catarrhalis. Bars refer to medians.sensitive (Fig. 3A) as previously described [15]. When tested in the
same assay, lavage ﬂuid from CF cohorts A and B as well as the control
cohort contained substantial amounts of SP-D which failed to bind zy-
mosan. Within control and CF lavage, a minor band migrating 3–4 kDa
and occasionally 6–8 kDa (Fig. 3B&C; closed arrows) higher than the
main SP-D monomer (Fig. 3B&C; asterisk) were sometimes identiﬁed
by western blot as part of the non-binding SP-D pool. Similar minor
forms of higher molecular weight SP-D have previously been described
[7,18]. Occasionally, a minor band migrating below the main SP-D
monomerwas observed in CF lavage which contained active neutrophil
elastase (Fig. 3B; open arrow). This likely corresponds to partially
proteolysed SP-D as previously described in CF [6,7]. Lavage SP-D inter-
actions with zymosan were also predominantly calcium and maltose
dependent (Fig. 3C). As reported in previous studies [9–11], calcium
chelationwith EDTA in CF lavage sometimes resulted in a loss of detect-
able SP-D due to proteolysis (data not shown). Protease inhibition with
1mM PMSF preserved SP-D under these conditions (Fig. 3C; right hand
panel). The pH of airway secretions in normal and pathological condi-
tions has been reported to be slightly acidic. The pH dependence of
SP-D zymosan interactions was therefore also tested and was found to
be stable when tested between pH5.6 and 7.6 (Fig. 3D).
Whenmaltose–agarose was used as a substrate for lavage ﬂuid SP-D
binding, the pattern of bindingwas largely similar to that obtainedwith
zymosan (Fig. 4). However in some cases (Fig. 4; samples 2b & 3b) SP-D
demonstrated weaker binding activity towards maltose–agarose.=25) and controls (n= 9) by sandwich ELISA. B) The CF cohort was divided into those
n=10) and those which either yielded nomicrobiological culture or yieldedmicroorgan-
s negative; n=15) as detailed in thematerials andmethods. Abbreviatedmicroorganisms
kholderia cepacia, S.malto.= Stenotrophomonas maltophilia, A. fum.=Aspergillus fumigatus,
Fig. 3.Assessing SP-D functional activity in CF and control lavageﬂuid: A) Native puriﬁed SP-Dwas incubatedwith awashed zymosan pellet in the presence of 10mMCaCl2, 10mMEDTA
or 10mM CaCl2 with 100mM D-maltose. Following a 30minute incubation with occasional agitation, zymosan was pelleted by centrifugation at 10,000 g/1min. Supernatants were care-
fully aspirated to fresh tubes. The pellet was washed in the appropriate buffer and treated with 20mM EDTA. Both pellet (P) and supernatant (S) fractions were boiled for 2min in SDS
sample buffer with β-mercaptoethanol prior to separation by SDS-PAGE on 10% gels followed byWestern blot for SP-D. SP-Dmobiliseswith the zymosan pellet in the presence of calcium
but not in the presence of maltose or EDTA. Data are representative of three or more independent experiments. B) Control and CF lavage as well as positive control native puriﬁed SP-D
were similarly assayed for their capacity to bind to zymosan in the presence of 10mMCaCl2. Themajority of native SP-Dmobilisedwith the zymosanpellet. In the case of both control (Co.)
and CFpatients, themajor SP-Dbandmigratedwith an identicalmolecularweight as native puriﬁed SP-D (*). A signiﬁcant proportion of SP-D in both control and CF lavage failed to bind to
zymosan and was found in the supernatant fraction. In addition to the main SP-D monomer additional bands migrating 3–4 and 6–8 kDa higher than the main SP-D monomer were ob-
served in some samples under reducing conditions (closed arrows) but only in the non-bound supernatant fraction. A minor lower molecular weight band, probably corresponding to a
proteolytic fragment of SP-D, was observed in a small number of samples (open arrow). Data are representative of at least 12 independent experiments. C) CF lavagewas incubatedwith a
washed zymosan pellet in the presence of 10 mM CaCl2, 10mM EDTA or 10mM CaCl2 with 100mM D-maltose as described in panel A. Following separation of pellet and supernatant
fractions by SDS-PAGE under reducing conditions, the majority of SP-D was seen to migrate with zymosan in a maltose and EDTA inhibitable fashion. Symbols refer to bands described
in panel B. Data are representative of at least 3 (maltose) and 2 (EDTA+PMSF) independent experiments. D) Zymosan binding assays were undertaken for three CF lavage ﬂuid samples
at pH 5.6, 6.6 and 7.6. No substantial differences in the proportion of bound and non-bound SP-D were observed between assays carried out at different pH.
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Following a zymosan binding assay and western blot of bound and
non-bound fractions, the percentage of zymosan bound SP-Dwas quan-
tiﬁed by densitometry for all available patient samples. In CF cohort A, 3/
25 samples with the lowest SP-D concentration contained insufﬁcient
antigen to be quantiﬁed in the zymosan binding assay and are not in-
cluded in subsequent analyses. In cohort B, 6/19 BALF samples were
similarly below the limit of detection for the assay. Those samples
below the limit of detection for western blot were also observed to
have SP-D b500ng/ml by ELISA. Further concentration of these samples
was not undertaken as this has been reported to alter the molecular
structure of SP-D in a functionally relevant manner [19]. A substantial
proportion of SP-D in lavage from CF cohort A failed to bind zymosan
(55%) and similar ﬁndings were observed in the control cohort (46%)
however there was no difference between the groups, (p = 0.56),
(Fig. 5A). Similar ﬁndings were observed in CF cohort B where 61% of
SP-D failed to bind zymosan (data not shown). The proportion of SP-D
with zymosan binding activity was signiﬁcantly lower in infected
compared to non-infected CF patients (p=0.02; Fig. 5B). The majority
of native puriﬁed SP-D included as a positive control in all assays for
cohorts A and B exhibited binding to zymosan (95%; 90–98).
Total zymosan binding SP-D (calculated using ELISA and zymosan
binding assay data) was higher in CF cohort A than controls (p=0.01;Fig. 6A) but was signiﬁcantly lower in CF samples with culture con-
ﬁrmed infection compared to those without (p=0.04; Fig. 6B).
Samples containing the lowest detectable SP-D zymosan binding
activity were tested for the ability to inhibit exogenously added native
SP-D binding to zymosan. Substantial inhibition of native SP-D binding
to zymosanwas not observed by lavage samples yielding a positive cul-
ture for A. fumigatus (Fig. 7), B. cepacia or S.maltophilia (data not shown)
suggesting that competitive inhibition bymicrobial ligandswithin these
samples was not responsible for the restricted lectin activity. Further-
more, addition of the serine protease inhibitor PMSF had little impact
on the assay results in the presence of calcium (Fig. 7).
In sampleswhere active elastasewas present, themajority of SP-D in
the non-bound fraction was of identical molecular weight to the bound
material and SP-D degradation products were only occasionally ob-
served in a small minority of samples by western blot (Fig. 3B). Despite
this, both the percentage and total concentration of SP-D with lectin ac-
tivity was signiﬁcantly lower in elastase positive samples from cohort A
compared to those in which elastasewas not detected (Fig. 8A & B). The
percentage and total concentration of SP-D binding to zymosan also
negatively correlated with expression of the neutrophilic chemokine,
IL-8, in this cohort, (Fig. 8C & D). Similar relationships between elastase
activity and SP-D lectin activity were not observed in cohort B (data not
shown), however those analyses may have been compromised by the
smaller sample size and the fact that almost half of the elastase positive
samples in that cohort were not detectable in the zymosan binding
Fig. 4. Assessing lavage SP-D binding activity towards zymosan and maltose agarose: CF
lavage was incubated either with maltose agarose (A) or zymosan (B) for 30 min in the
presence of 10mMCaCl2. Native puriﬁed SP-Dwas included as a positive control. Follow-
ing centrifugation, the supernatant (S) fraction was carefully aspirated. The pellet (P)
fraction was washed and resuspended in 20mM EDTA. Both fractions were separated by
SDS-PAGE under reducing conditions and blotted for SP-D. In addition to the main SP-D
monomer, a minor population of SP-D migrating 3–8 kDa above this was evident in the
non-bound supernatant. Additional bandsmigrating at approximately 95kDa are thought
to represent partially non-reduced SP-D dimers. Data are representative of 3 independent
experiments addressing 10 distinct lavage ﬂuid samples.
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CXCL8 expression data was not available in cohort B.
3.4. Oligomeric variants of SP-D in CF airway lavage ﬂuid exhibit distinct
lectin activity
As the oligomeric status of SP-D is known to have a profound impact
on its ligand binding activity [20–22], native gel electrophoresis was
used to assess the oligomeric status of SP-D in lavage ﬂuid. A range of
oligomeric forms were evident in both control and CF samples
(Fig. 9A) including very large oligomers barely capable of entering the
gel. Analysis of bound and non-bound fractions from a zymosan bindingFig. 5. SP-D zymosan binding activity in CF and control lavage: A) All available lavage samples
natant fractions, blots were probed for SP-D. The percentage of SP-D associatedwith the zymosa
Data are presented for control (n=9) and CF cohort A (n=22; 3 CF samples had too little SP-D
with clinically important infections (infection status positive: n=7; 3 CF samples had too little
15) as described in the materials and methods. The identities of the infectious microorganismsassay, revealed that high oligomeric forms of SP-D predominantly mi-
grated with zymosan whilst low oligomeric forms remained in the su-
pernatant (Fig. 9B; upper panel). Intermediate oligomeric forms
evident in the non-fractionated blot (arrow; Fig. 9A), were less preva-
lent following the binding assay. Partial assembly of SP-D trimers to
multimers in response to ligand binding has previously been reported
[19] and we suggest that these intermediate forms may have formed
larger oligomers in response to zymosan binding.
The size distribution of SP-Dwas also examined by gel chromatogra-
phy of lung lavage ﬂuid from six CF patients. Two distinct populations of
SP-D separating at different molecular weights were observed in all
samples tested (Fig. 10A). Although present in different proportions,
both populations eluted at the same position in all lavage samples.
Themobility of both populations relative to globular standardswas con-
sistent with ‘high’ (dodecameric and multimeric) and ‘low’ (trimeric)
forms of SP-D previously described by Leth-Larsen [22]. Fractions from
ﬁve of these samples were available for parallel assays of lectin activity.
This showed substantial calcium dependent SP-D mannan binding ac-
tivity in fractions corresponding to high oligomeric forms whilst SP-D
in fractions of lower oligomeric form exhibited only weak or absent
mannan binding activity in any of the samples tested (Fig. 10B & C).
4. Discusssion
We present a comprehensive analysis of SP-D expression and func-
tion in lung secretions from paediatric CF patients and controls. To our
knowledge, this is the ﬁrst systematic analysis of SP-D lectin activity in
the CF population.
In keeping with previous studies, SP-D expression was reduced in
lavage ﬂuid fromCF patientswith infection or evidence of inﬂammation
compared to non-infected CF patients. Importantly however, SP-D was
present in all but a few CF samples representing both bronchial (Cohort
A) and bronchoalveolar (Cohort B) airway when tested by speciﬁc dual
monoclonal antibody ELISA. There has been considerable variability in
reported values for BALF SP-D in CF, ranging from a near absence
[4,23] to expression in the μg/ml range [5]. Several factors may explain
this variability: In addition to differences in BAL sampling and process-
ing methodology, techniques used to measure SP-D in CF range from
semi-quantitative western blot [6,7] to ELISA, some of which use anti-
bodies reactive with human SP-D but raised against different species
[5,23]. Also, some previous studies applied speciﬁc microbial density
thresholds to deﬁne infection [5,6], whereas we deﬁne infection on
the basis of reported positive culture in line with other reportswere subjected to a zymosan binding assay and following SDS-PAGE of pellet and super-
n pellet was quantiﬁed by analysis of pellet and supernatant bands using ImageJ software.
to be quantiﬁed by the zymosan binding assay). B) CF samples were separated into those
SP-D to be quantiﬁed by the zymosan binding assay) or not (infection status negative: n=
are detailed in abbreviated form as detailed in the legend to Fig. 1b. Bars refer to medians.
Fig. 6. SP-D binding activity in CF and control lavage: Data from the zymosan binding assay was combinedwith that from the ELISA to calculate the amount of lavage SP-Dwith zymosan
binding activity. A) Data are presented for control (n=9) and CF cohort A (n=22; 3 CF samples had too little SP-D to be quantiﬁed by the zymosan binding assay). B) CF samples were
separated into those with clinically important infections (infection status positive: n=7; 3 CF samples had too little SP-D to be quantiﬁed by the zymosan binding assay) or not (infection
status negative: n=15) as described in thematerials andmethods. The identities of the infectiousmicroorganisms are detailed in abbreviated formas detailed in the legend to Fig. 1b. Bars
refer to medians.
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both by western blot and ELISA even in culture positive CF samples.
Also, in some previous studies, the proportion of patients with culture
veriﬁed infection was higher [4,7] and the age range of CF patients sub-
stantially older [7,23] than those studied by us. This may be relevant in
light of the negative correlation between age, infection and SP-D con-
centration reported here. Previous population based studies have
described increased circulating SP-D with age [27]. The age related de-
cline in lung rather than circulating SP-D observed here probably
reﬂects advancing lung disease in this population, an interpretation
supported by the increased prevalence of infection and active elastase
in older patients. In summary, our observation of substantial SP-D
expression in CF conﬁrms some reports [5,7] but not others [4]. Howev-
er the observed negative association between SP-D, infection and
inﬂammation agrees with the ﬁndings of a number of previous studies
[4–6] and suggests that detectable SP-D is subject to dynamic modula-
tion in the face of ongoing inﬂammatory disease.
The primary objective of this studywas to examine the carbohydrate
binding activity of SP-D in CF patients. We observed considerable het-
erogeneity in the capacity of both CF and control lavage SP-D to bindFig. 7. Culture positive CF lavage with minimal endogenous functional SP-D does not sub-
stantially inhibit exogenous native SP-D binding activity towards zymosan: CF lavage
which yielded positive microbiological culture and was found to contain SP-D with
weak capacity to interact with zymosan was tested for its ability to inhibit exogenously
added native SP-D binding to zymosan. Experiments were carried out in the presence or
absence of 1mM PMSF to inhibit serine protease activity present in these samples. Lavage
ﬂuid was reconstituted with (+NhSP-D) or without (−NhSP-D) puriﬁed native SP-D.
Positive controls in the absence of lavagewere also included (lanes 1–4). Sampleswere in-
cubated with zymosan in the presence of 10 mM CaCl2. Following centrifugation, pellet
and supernatant fractions were separated by SDS-PAGE under reducing conditions and
blotted for SP-D. The majority of exogenously added SP-D bound to zymosan in these ex-
periments and PMSF had little impact on binding activity in the presence of 10mM CaCl2.
Data are representative of 3 independent experiments.the yeast derived mannan rich particle, zymosan. Such heterogeneity
was observed in lavage ﬂuid collected from two distinct cohorts of CF
patients. Lavage collected from cohort A was mainly of bronchial origin
whilst that from cohort B was reﬂective of bronchoalveolar lavage
according to the lavage procedure used. Nevertheless, inﬂammatory ac-
tivity (reﬂected in free elastase activity) was relatively similar between
both cohorts which may reﬂect the largely bronchial nature of airway
disease in CF. Although SP-D inactivation by CF relevant proteases is
well described, the functional consequences of this remain unclear as
physiological concentrations of calcium render SP-D resistant to prote-
olysis [6,9,11]. As previously reported, SP-D expression was lower in
elastase positive CF samples here, however in themajority of cases sub-
strate bound and non-bound SP-D migrated at an identical molecular
weight on SDS-PAGE under reducing conditions. The absence of a
major population of proteolytically fragmented SP-D in this study is
consistent with two previous reports [7,12] and indicates that limited
proteolysis is not responsible for the observed restriction of lectin activ-
ity. Minor forms of SP-Dmigrating 3–8kDa higher than themainmono-
mer were observed in many samples but did not associate with
zymosan or maltose–agarose and were exclusively found in the super-
natant fraction. These resemble forms of SP-D previously observed in
CF BALF [7] and are thought to represent a hyper-glycosylated form of
SP-D speculated byMason et al. to limit oligomerisation to trimeric spe-
cies [18]. The inability of these forms to bind saccharide ligands in our
assays is consistent with the well documented reduction of opsonic
and anti-viral activity of low oligomeric forms of SP-D [20–22]. In light
of this, we used both native gel electrophoresis and size exclusion chro-
matography to further investigate the molecular distribution and lectin
activity of SP-D in airway lavage. SP-D capable of binding zymosan ex-
hibited features of high molecular weight when assessed by western
blot under native conditions, whilst non-bound material was of lower
molecular weight. This observation was conﬁrmed by size exclusion
chromatography which revealed two populations of SP-D in CF airway
lavage ﬂuid. Consistent with data from the zymosan binding assay,
high molecular weight SP-D bound to yeast derived mannan in a calci-
um dependent fashion whilst lower molecular weight material exhibit-
ed limited if any capacity to recognise such polysaccharides. The
distribution of these two populations of SP-D is consistent with reports
of a common SP-D polymorphism inﬂuencing the structure and lectin
activity of SP-D. The presence of Thr at position 11 limits SP-D
oligomerisation to trimers with restricted lectin activity whilst Met at
that position gives rise to dodecameric oligomers with unrestricted
lectin activity towards complex carbohydrates and a range of bacteria
Fig. 8. The percentage and amount of functional SP-D in CF lavage are inversely related to neutrophil elastase activity and IL-8 expression: CF lavage sampleswith sufﬁcient SP-D to enable
analysis in the zymosan binding assay were separated into those samples with detectable elastase activity (elastase status positive; n= 11) or not (elastase status negative; n= 11) in
order to assess differences in the percentage (A) and amount (B) of SP-D capable of binding to zymosan between these two groups. Bars refer to medians, p-values refer to the Mann–
Whitney test. The percentage (C) and amount (D) of SP-D capable of binding to zymosan were also plotted against IL-8 concentration for each sample (n = 22 in both cases). R- and
p-values refer to Spearman's correlation.
Fig. 9. Lavage SP-D with zymosan binding activity exhibits features of higher oligomeric
form: A) CF and control lavage ﬂuid was separated on 3–8% Tris-acetate polyacrylamide
gels under native conditions. Following transfer to nitrocellulose, blots were probed for
SP-D. B) CF and control lavage as well as positive control native puriﬁed SP-D were
subjected to a zymosan binding assay in the presence of 10 mM CaCl2. Zymosan bound
(pellet;P) and non-bound (supernatant;S) fractions were isolated and prepared for either
native PAGE (top panel) or SDS-PAGE under reducing conditions (bottom panel). Under
native conditions the majority of zymosan bound material in the pellet fraction exhibited
features of high oligomeric form and was unable to signiﬁcantly migrate into the gel. By
contrast, non-bound material from the supernatant migrated with characteristics of
lower oligomeric form. The arrow in panel A highlights an intermediate oligomeric form
of SP-D observed in unfractionated lavage which was less prevalent following the zymo-
san binding assay.
2398 S. Kotecha et al. / Biochimica et Biophysica Acta 1832 (2013) 2391–2400and Inﬂuenza virus in addition to functionally restricted trimeric oligo-
mers [22]. Although the frequency of that polymorphismwas not deter-
mined here, its distribution amongst Danish CF patients is not
signiﬁcantly different from the normal population [28]. In addition to
these common polymorphisms, post-translational modiﬁcation by
nitric oxide derivatives [29] and elements of the neutrophil respiratory
burst [30,31] also contribute to plasticity of SP-D structure and function.
Reactive oxygen–nitrogen intermediates of the innate inﬂammatory re-
sponsewere not reported to have any appreciable impact on SP-D lectin
activity when tested using similar pulldown methodology as that
employed here; rather, these intermediates diminished the agglutinat-
ing activity of SP-D [30,31]. Importantly, agglutination is not a critical
determinant of zymosan mobility under the assay conditions used
here. Taken together, this suggests that the functional heterogeneity
reported here is not primarily due to post-translational modiﬁcations
by reactive oxygen–nitrogen intermediates. However, a thorough as-
sessment of the presence of such post-translational modiﬁcations in
clinical BAL samples will be required to fully understand the impact of
these processes on SP-D activity in vivo.
Lower zymosan binding activity was observed amongst SP-D
from CF patients with clinically important infections. Although the
number of patients with infections was limited owing to the lower
rates of chronic infection in the paediatric CF population, the data
nevertheless demonstrate signiﬁcant differences in the expression
and lectin activity of SP-D in the face of infection. One interpretation
of this ﬁnding, and that of reduced SP-D expression in infected pa-
tients, is that sequestration by adherence to bacteria and subsequent
clearance during lavage processing explains the observed deﬁcit.
Fig. 10. Two populations of SP-D of different oligomeric form and exhibiting distinct lectin
activity are present in CF airway ﬂuid: A) Six CF lavage ﬂuid samples were subjected to
Superose 6 gel ﬁltration and fractions were assessed for SP-D content by ELISA. Two dis-
tinct peaks of different molecular weight were observed in all samples tested. The elution
proﬁle of three standards – blue dextran (BD), thyroglobulin (TG) and alcohol dehydroge-
nase (ADH) – and their molecular weights are indicated at the top of the panel. B) For ﬁve
of the samples separated by gel ﬁltration, individual fractionswere also assessed for calci-
um dependent SP-D binding to mannan in a solid phase assay. Larger molecular weight
SP-D oligomers bound to mannan but little or no binding was observed from the lower
molecular weight fractions. C) The inclusion of EDTA inmannan binding assays was sufﬁ-
cient to inhibit all SP-D/mannan interactions.
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address this possibility, a previous study of CF and non-CF patients
with and without infection, indicates that poorly regulated inﬂam-
mation rather than infection per se, is responsible for SP-D depletion
during infectious disease [5]. That study also reported no difference
in SP-D content between sonicated, cellular BALF and cleared acellu-
lar BALF, nor did EDTA treatment of BALF prior to clearance (to dis-
sociate any potential SP-D complexes) have any effect on SP-D
content. Our own unpublished data conﬁrm the enhanced anti-
viral properties of size excluded high oligomeric form alveolar
proteinosis SP-D towards Inﬂuenza-A virus. Intriguingly, these high-
ly oligomerised forms of SP-D also agglutinate Escherichia coli intovery large aggregates (up to 50μm and occasionally 80μm diameter;
data not shown) and may play an important role in facilitating effec-
tive mucociliary clearance of bacteria from the lower airway; a
process likely to be of critical importance in the CF airway. It is pos-
sible that enhanced mucociliary clearance of large aggregates may
partially explain the depressed SP-D expression in the airway of CF
patients with infection observed here and elsewhere. This would
be predicted to lead to the preferential clearance of higher order
oligomers of SP-D from the lower airway, which may also explain
the relatively restricted lectin activity of SP-D in CF patients with
infection, where lower order oligomers would dominate. Neverthe-
less, even amongst non-infected and control patients, considerable
heterogeneity of SP-D lectin activity was observed. We have recently
described functionally relevant heterogeneity of SP-D oligomeric
form in preterm neonatal BALF using methodology similar to that
described here [15]. Oligomeric diversity has also been observed in
SP-D from asthmatic and chronic obstructive pulmonary disease
patients [32,33] but was not examined functionally. Few other sys-
tematic reports of SP-D activity in clinical populations have been
published. One study reported maltose inhibitable agglutinating
activity of BALF from tracheostomy patients towards P. aeruginosa
as a surrogate measure of SP-D agglutinating activity [34]. Interest-
ingly, although the agglutinating activity of lavage correlated with
SP-D content, this was found to be a relatively weak association indi-
cating either that other maltose inhibitable factors were contribut-
ing to the activity, or that not all SP-D detected by ELISA
participated in the agglutinating activity. In light of data reported
here and previously [15] we argue that it is important to rely not
only on quantitative assays of SP-D content when considering the
status of SP-D in a clinical population but also to consider what
proportion of the recovered material is functionally active in any
given assay. It is also important to consider what aspect of SP-D ac-
tivity one wishes to measure. Both lectin and agglutinating activity
are profoundly inﬂuenced by the oligomeric state of SP-D however
how this inﬂuences the reported anti-inﬂammatory activity of SP-D
is not well understood. Understanding this relationship will be an
important step in fully understanding the inﬂuence of SP-D oligo-
meric diversity upon the range of reported SP-D activities.
The importance of SP-D oligomeric state in controlling infection
in vivo is also not well understood. Heritable variation in SP-D
oligomerisation has been implicated in clinically relevant responses to
respiratory syncytial virus [35,36] andMycobacterium tuberculosis [37].
In the case of MBL (another collectin subject to functionally relevant
oligomeric variation), amino acid changes inﬂuencing multimerisation
and carbohydrate binding activity act in combination with promoter
polymorphisms to confer a state of functional and quantitative MBL in-
sufﬁciency [38] associated with earlier and more severe lung pathology
in CF [39]. Increased oligomeric complexity in SP-A has also been re-
cently associated with better lung function in CF [40]. The only study
published to date in CF identiﬁed no association between SP-D Met/
Thr genotype and disease progression [28], however larger studies
looking at the full range of factors inﬂuencing SP-D structure/function
will probably be required to reach a ﬁrm conclusion.
In summary, our data show that SP-D is found in substantial quanti-
ties in the paediatric CF lung but exists as a functionally and structurally
heterogeneous population in both this and the control population. As
our surgical control population did not have symptoms of airway dis-
ease at the time of sampling it will be interesting to examine SP-D ex-
pression and lectin activity in non-CF patients with suppurative lung
disease to examine whether the link between infection, inﬂammation
and SP-D activity observed here is a speciﬁc feature of CF. We propose
that structural heterogeneity may be as important (if not more so)
than proteolytic digestion in determining the functionality of SP-D in
CF. Although factors inﬂuencing SP-D oligomerisation have been identi-
ﬁed, how this may differ in health and disease and the contribution this
makes to clinical outcome requires further investigation.
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